a process that can take many years. BioPharma Services helps companies ensure that drugs that are being developed are safe and effective. Take a look at our Frequently Asked Questions and other volunteer pages to learn more about how you can become involved by participating in a Clinical Trial....
In the first half of 2022, Henlius has closed over multiple out-licensing deals for Henlius' four biosimilars on the market and other products in development. Through commercial collaborations with overseas pharmaceutical companies, the...
In the first half of 2022, Henlius has closed over multiple out-licensing deals for Henlius' four biosimilars on the market and other products in development. Through commercial collaborations with overseas pharmaceutical companies, the company aimed to further promote the entry of self-developed produ...
We serve all companies within the life sciences ecosystem. Whether your company operates in the biotechnology, medical technology, pharmaceutical or clinical sector, we have a solid understanding of your product(s) and target market. Explore LeadGen 360 ...
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead.
Bringing more biomanufacturing to the UK also supports the country’s rapidly growing life sciences sector. In 2021, £4.5 billion ($6 billion) was raised in public and private financing by UK biotech companies, a 60% increase compared to 20201. While the UK leads Europe with ...
As we have shown in our series of reports on ‘Measuring the return from pharmaceutical innovation’, these factors are contributing to an alarming decline in the projected return on investment that large biopharma companies might expect to achieve from their late-stage pipelines, threatening their ...
Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
(CROs/CDMOs), where several of our clients are emerging biopharma, Syngene understands these challenges. We have partnered with many biopharma companies, supporting them in their drug development journey from idea to commercial. Our experienced team of scientists anticipate your needs well in advance...
Digital technologies, which are driving massive transformation in health care, can help biopharma companies innovate to develop products and services, engage better with consumers, and execute operations more effectively.